Report Research & Recommendations

[Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)

[Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)

The English version of the file has been published. (June 18, 2024) 

Health and Global Policy Institute (HGPI) has offered policy recommendations and taken a number of other activities to promote patient and public involvement (PPI) in policy development process, under our stated mission of “Achieving citizen-centered health policy.” Recently, initiatives for PPI in processes of health policy development are now being advanced at both the national Government and local level at councils. However, new issues have been recognized consequently, which include lack of the diversities in and the number of individuals who desire to be involved. Based on our recognition of these issues, our PPI Support Project this fiscal year aims to promote the involvement of diverse patient and public representatives into policy development process.

Based on our discussions to date, we have compiled a ” Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government.” This guidance reviews how PPI in the policymaking process is important and outlines the initiatives that are required in the future to promote it. Please refer to the PDF file at the end of this document for the details of this guide.


FY2023 Advisory Board Members (Titles omitted; in Japanese alphabetical order by last name, absent members included)

Kyoko Ama (Representative, Children and Healthcare Project; Fellow, HGPI)
Shinsuke Amano (Chair, The Japan Federation of Cancer Patient Groups; CEO, Group Nexus Japan)
Etsuko Aruga (Professor, Department of Palliative Medicine, Teikyo University School of Medicine)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Takeshi Shukunobe (President and CEO, PPeCC)
Kazuyuki Suzuki (Senior Lead, Patient Engagement Group, Strategy & Execution, Novartis Pharma K.K.)
Yasuhiro Sensho (CEO, SENSHO-GUMI, Co., Ltd.; Former Director-General, MHLW)
Teppei Maeda (Lawyer, Maeda & Unosawa Law Offices; Representative, Medical Basic Act Community)
Kaori Muto (Professor, Department of Public Policy Studies, Institute of Medical Science, University of Tokyo)
Akira Morita (Representative Director, Next Generation Fundamental Policy Research Institute (NFI))
Ikuko Yamaguchi (Chief Director, Consumer Organization for Medicine and Law (COML))
Risa Yamazaki (Public Affairs Group, External Affairs Department, Chugai Pharmaceutical Co., LTD.)

 

Project sponsors (in Japanese alphabetical order)
National Graduate Institute for Policy Studies (GRIPS) Global Health Innovation Policy Program
Syneos Health Commercial K.K.
Chugai Pharmaceutical Co., Ltd.
Novartis Pharma K.K.

 

Guidance/brochure

Guidance Brochure
For Web For Print
Please print in landscape orientation, double-sided (short edge binding), and fold in half.
Back to Research & Recommendations
PageTop